Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Assessing the Impact of the 2021 VWD Guidelines on the Diagnosis/Management of Low VWF Patients.

Haemophilia : the official journal of the World Federation of Hemophilia·2026

Same author

Evaluating the accuracy of point of care testing compared to standard laboratory testing among inborn infants in the neonatal intensive care unit.

Journal of perinatology : official journal of the California Perinatal Association·2025

Same author

Epstein-Barr virus and multiple sclerosis: A mechanism comes into focus.

Multiple sclerosis and related disorders·2025

Same author

Urinary biomarkers of acute kidney injury in neonates < 25 weeks' gestation: a pilot study.

Pediatric nephrology (Berlin, Germany)·2025

Same author

Evaluating the accuracy of point of care testing compared to standard laboratory testing among inborn infants in the neonatal intensive care unit.

Research square·2025

Same author

Interactive associations of eczema with glutathione S-transferase genes in relation to autism spectrum disorder and its severity in Jamaican children.

Research in autism spectrum disorders·2025

Same journal

Neuromyelitis optica spectrum disorder: a 5-year experience in a tertiary hospital in Northern Vietnam.

Multiple sclerosis and related disorders·2026

Same journal

Cell-type-specific Mendelian randomization analysis of brain single-nucleus eQTLs and neuromyelitis optica spectrum disorder risk.

Multiple sclerosis and related disorders·2026

Same journal

Detection of Aquaporin-4 antibody in cerebrospinal fluid in neuromyelitis optica spectrum disorder.

Multiple sclerosis and related disorders·2026

Same journal

Adjunctive gypenosides for acute optic neuritis: A prematurely terminated randomized, double-blind, placebo-controlled pilot trial in a cohort with frequent AQP4-IgG positivity.

Multiple sclerosis and related disorders·2026

Same journal

Genetic and molecular architecture of multiple sclerosis in gulf cooperation council populations: A scoping review and regional precision-neurology perspective.

Multiple sclerosis and related disorders·2026

Same journal

Rising burden and future projections of multiple sclerosis in East Asia: Findings from the global burden of disease study 2021.

Multiple sclerosis and related disorders·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Aug 15, 2025

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line

Published on: September 28, 2022

The concentrations of antibodies to Epstein-Barr virus decrease during ocrelizumab treatment.

H Phuong T Pham¹, Sepideh Saroukhani², J William Lindsey¹

¹Department of Neurology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas, USA.

Multiple Sclerosis and Related Disorders

|January 5, 2023

Summary

This summary is machine-generated.

Ocrelizumab (OCR) treatment for multiple sclerosis (MS) reduces antibodies to Epstein-Barr Virus (EBV) antigens. This suggests OCR may benefit MS patients by decreasing the EBV antigenic stimulus.

Keywords:

B cell depletion Epstein-Barr virus Multiple sclerosis Ocrelizumab antibody response

More Related Videos

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Published on: November 8, 2011

Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis

Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis

Published on: September 7, 2022

Related Experiment Videos

Last Updated: Aug 15, 2025

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line

Published on: September 28, 2022

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Published on: November 8, 2011

Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis

Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis

Published on: September 7, 2022

Area of Science:

Immunology
Virology
Neurology

Background:

Epstein-Barr Virus (EBV) infection is linked to multiple sclerosis (MS).
EBV establishes lifelong latent infection in B lymphocytes.
Ocrelizumab (OCR), an anti-CD20 antibody, depletes B cells and reduces MS disease activity.

Purpose of the Study:

To investigate the impact of OCR treatment on antibody responses to EBV antigens.
To assess antibody responses to human antigens cross-reactive with EBV during OCR therapy.

Main Methods:

Blood samples from MS patients before and during OCR treatment were analyzed.
Antibodies to EBV antigens (EBNA-1, BFRF3, gp350) and cross-reactive human proteins (septin-9, DLST, HNRNPL) were measured using Western blots and ELISA.

Main Results:

OCR treatment significantly decreased antibodies to EBV antigens EBNA-1 and BFRF3 after 12 months.
A trend towards decreased antibody response to cross-reactive human proteins septin-9 and DLST was observed.
No significant change in antibodies to HNRNPL or total IgG concentration was noted.

Conclusions:

Ocrelizumab treatment leads to a reduction in antibody responses to specific EBV antigens in MS patients.
The therapeutic benefit of OCR in MS may involve mitigating the EBV antigenic stimulus.